Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized placebo-controlled Phase I/IIa study of TOL2 in generalized myasthenia gravis
2024-515627-10-00Phase 2Authorised
- Sponsor
- Bonsai Biotherapeutics
- Start
- Feb 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing TOL2 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events, Local tolerability reactions and 2 more. Planned start Feb 2025; status: authorised.
02
Drugs
TOL2
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-515627-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515627-10-00.